TURNOVER (x1000 EUR)
NET PROFIT (x1000 EUR)
EMPLOYEES
Xvivo Perfusion AB
Closing information (x1000 EUR)
Closing information | 2022/12 (consolidated) | 2021/12 (consolidated) | 2020/12 (consolidated) |
Turnover |
37,319
|
25,265
|
17,919 |
Financial expenses |
5,005
|
1,976
|
1,243 |
Earnings before taxes |
2,005
|
652
|
-5,705 |
EBITDA |
4,365
|
-729 | |
Total assets |
155,737
|
150,837
|
114,601 |
Current assets |
42,011
|
53,538
|
46,150 |
Current liabilities |
12,122
|
10,220
|
7,198 |
Equity capital |
128,513
|
125,693
|
100,469 |
- share capital |
68
|
74
|
68 |
Employees (average) |
114
|
92
|
63 |
Financial ratios
Fiscal year | 2022/12 (consolidated) | 2021/12 (consolidated) | 2020/12 (consolidated) |
Solvency |
82.5%
|
83.3%
|
87.7% |
Turnover per employee |
327
|
275
|
284 |
Profit as a percentage of turnover |
5.4%
|
2.6%
|
-31.8% |
Return on assets (ROA) |
4.5%
|
1.7%
|
-3.9% |
Current ratio |
346.6%
|
523.9%
|
641.2% |
Return on equity (ROE) |
1.6%
|
0.5%
|
-5.7% |
Change turnover |
14,100
|
7,678
|
-4,082 |
Change turnover % |
61%
|
44%
|
-19% |
Chg. No. of employees |
22
|
29
|
17 |
Chg. No. of employees % |
24%
|
46%
|
37% |
Total value of public sale
Fiscal year | 2022/12 (consolidated) | 2021/12 (consolidated) | 2020/12 (consolidated) |
Total value of public sale |
0
![]() |
0
![]() |
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.